• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Pfizer Seeks EUA for COVID-19 Vaccine in Children


The announcement was made by Pfizer and BioNTech on Twitter

Pfizer announced on Twitter that it and BioNTech have officially asked for an emergency use authorization (EUA) for its COVID-19 vaccine for children 5 to 11 years of age.

The companies announced positive topline results from the pivotal trial on Sept. 20, 2021, and they began submitting data from this trial to the FDA on Sept. 28.

In the trial, which included 2,268 participants 5 to less than 12 years of age, the vaccine demonstrated a favorable safety profile and elicited antibody responses using a two-dose regimen of 10 μg doses. These results were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age, who were immunized with 30 μg doses. The 10 μg dose was selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to less than 12 years of age.

Related: Pfizer and BioNTech Submit Initial Data of COVID-19 Vaccine in Children

Related Content
© 2024 MJH Life Sciences

All rights reserved.